EE03955B1 - Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks - Google Patents
Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseksInfo
- Publication number
- EE03955B1 EE03955B1 EE9700133A EE9700133A EE03955B1 EE 03955 B1 EE03955 B1 EE 03955B1 EE 9700133 A EE9700133 A EE 9700133A EE 9700133 A EE9700133 A EE 9700133A EE 03955 B1 EE03955 B1 EE 03955B1
- Authority
- EE
- Estonia
- Prior art keywords
- cells
- nucleic acid
- transfecting
- medicament
- manufacture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9426380.3A GB9426380D0 (en) | 1994-12-24 | 1994-12-24 | Regulation of endometrial function by in vivo gene transfer |
GBGB9520879.9A GB9520879D0 (en) | 1994-12-24 | 1995-10-12 | Improvements in or relating to endometrial function |
PCT/GB1995/003008 WO1996020013A1 (en) | 1994-12-24 | 1995-12-21 | Improvements in or relating to endometrial function |
Publications (2)
Publication Number | Publication Date |
---|---|
EE9700133A EE9700133A (et) | 1997-12-15 |
EE03955B1 true EE03955B1 (et) | 2003-02-17 |
Family
ID=26306279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9700133A EE03955B1 (et) | 1994-12-24 | 1995-12-21 | Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks |
Country Status (23)
Country | Link |
---|---|
US (2) | US6472374B1 (da) |
EP (1) | EP0799058B1 (da) |
JP (2) | JPH10511548A (da) |
KR (1) | KR20050052548A (da) |
CN (1) | CN1241646C (da) |
AT (1) | ATE234637T1 (da) |
AU (1) | AU712278B2 (da) |
BG (1) | BG63332B1 (da) |
BR (1) | BR9510408A (da) |
CA (1) | CA2208446A1 (da) |
CZ (1) | CZ293770B6 (da) |
DE (1) | DE69530001T2 (da) |
DK (1) | DK0799058T3 (da) |
EE (1) | EE03955B1 (da) |
ES (1) | ES2323909T3 (da) |
HU (1) | HU221204B1 (da) |
MX (1) | MX9704765A (da) |
NO (1) | NO320436B1 (da) |
NZ (1) | NZ297537A (da) |
PL (1) | PL192784B1 (da) |
PT (1) | PT799058E (da) |
SK (1) | SK284119B6 (da) |
WO (1) | WO1996020013A1 (da) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777639B2 (en) * | 2002-06-12 | 2004-08-17 | Nanotechnologies, Inc. | Radial pulsed arc discharge gun for synthesizing nanopowders |
US7704965B2 (en) | 2002-06-26 | 2010-04-27 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
US7012214B2 (en) * | 2003-09-24 | 2006-03-14 | Nanotechnologies, Inc. | Nanopowder synthesis using pulsed arc discharge and applied magnetic field |
EP1687022A4 (en) | 2003-11-12 | 2008-02-13 | Medical Res Council | RENTA: HIV IMMUNOGEN, AND USES OF RENTA |
DK2399602T3 (da) | 2006-06-02 | 2015-02-23 | Int Aids Vaccine Initiative | Hiv-1 clade-a-konsensussekvenser, antigener og transgener |
US20080050814A1 (en) * | 2006-06-05 | 2008-02-28 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
WO2007146106A2 (en) * | 2006-06-05 | 2007-12-21 | Cryo- Cell International, Inc. | Procurement, isolation and cryopreservation of maternal placental cells |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP2701736A1 (en) | 2011-04-25 | 2014-03-05 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
WO2014040025A2 (en) | 2012-09-10 | 2014-03-13 | International Aids Vaccine Initiative | Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9925258B2 (en) | 2015-10-02 | 2018-03-27 | International Aids Vaccine Initiative | Replication-competent VSV-HIV Env vaccines |
KR101802090B1 (ko) * | 2016-09-26 | 2017-11-27 | 서울대학교산학협력단 | 탈락막 자궁내막 세포를 포함하는 자궁내막 손상의 치료용 조성물 |
CA3161633A1 (en) | 2019-11-14 | 2021-05-20 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
US20210338804A1 (en) | 2020-02-21 | 2021-11-04 | International Aids Vaccine Initiative Inc. | Vaccine Compositions For Preventing Coronavirus Disease |
CN112458161A (zh) * | 2020-11-12 | 2021-03-09 | 深圳市锦欣医疗科技创新中心有限公司 | 一组子宫内膜容受性生物标志物、试剂盒及判断子宫内膜容受性的方法 |
KR20220083029A (ko) * | 2020-12-11 | 2022-06-20 | 주식회사 커스토젠 | 자궁내막 비후용 약학적 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
WO1994005782A1 (en) * | 1992-09-10 | 1994-03-17 | Trustees Of Tufts College | In vivo production of transgenic organ by introducing the transgene via lumen |
GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
-
1995
- 1995-12-21 PL PL324088A patent/PL192784B1/pl not_active IP Right Cessation
- 1995-12-21 AU AU42707/96A patent/AU712278B2/en not_active Ceased
- 1995-12-21 PT PT95941229T patent/PT799058E/pt unknown
- 1995-12-21 HU HU9702205A patent/HU221204B1/hu not_active IP Right Cessation
- 1995-12-21 CZ CZ19971917A patent/CZ293770B6/cs not_active IP Right Cessation
- 1995-12-21 AT AT95941229T patent/ATE234637T1/de not_active IP Right Cessation
- 1995-12-21 EP EP95941229A patent/EP0799058B1/en not_active Expired - Lifetime
- 1995-12-21 KR KR1020057008617A patent/KR20050052548A/ko not_active Application Discontinuation
- 1995-12-21 DK DK95941229T patent/DK0799058T3/da active
- 1995-12-21 CA CA002208446A patent/CA2208446A1/en not_active Abandoned
- 1995-12-21 ES ES95941229T patent/ES2323909T3/es not_active Expired - Lifetime
- 1995-12-21 EE EE9700133A patent/EE03955B1/xx not_active IP Right Cessation
- 1995-12-21 CN CNB951974637A patent/CN1241646C/zh not_active Expired - Fee Related
- 1995-12-21 NZ NZ297537A patent/NZ297537A/xx unknown
- 1995-12-21 BR BR9510408A patent/BR9510408A/pt not_active Application Discontinuation
- 1995-12-21 SK SK801-97A patent/SK284119B6/sk unknown
- 1995-12-21 DE DE69530001T patent/DE69530001T2/de not_active Expired - Fee Related
- 1995-12-21 JP JP8520293A patent/JPH10511548A/ja active Pending
- 1995-12-21 WO PCT/GB1995/003008 patent/WO1996020013A1/en active IP Right Grant
- 1995-12-21 US US08/860,047 patent/US6472374B1/en not_active Expired - Fee Related
- 1995-12-21 MX MX9704765A patent/MX9704765A/es not_active IP Right Cessation
-
1997
- 1997-06-23 NO NO19972935A patent/NO320436B1/no unknown
- 1997-07-01 BG BG101714A patent/BG63332B1/bg unknown
-
2002
- 2002-09-24 US US10/252,404 patent/US20030186907A1/en not_active Abandoned
-
2006
- 2006-01-13 JP JP2006006212A patent/JP2006124402A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE03955B1 (et) | Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks | |
DE69019009D1 (de) | Zellkulturverfahren. | |
MX9703063A (es) | Compuestos de ester y acido boronico, su sintesis y usos. | |
YU47800B (sr) | Estri tienil-karboksilne kiseline sa aminoalkoholima, njihova kvaterna jedinjenja kao i pripremanje tih jedinjenja | |
DE68901782D1 (de) | Brennstoffzelle, elektrode fuer die zelle und verfahren zur herstellung. | |
DE3580283D1 (de) | Biologisch wirksame substanz mit hormonellen eigenschaften, verfahren zu ihrer herstellung und verwendung von histonen fuer medizinische zwecke. | |
CA2058930A1 (en) | Media for cell growth and method for making them | |
DE3583170D1 (de) | Elektrode fuer brennstoffzelle, verfahren zu ihrer herstellung und diese elektrode verwendende brennstoffzelle. | |
IE830945L (en) | Process for obtaining permanently culturable animal and¹human cell lines | |
IT7928062A0 (it) | 4(3h)-chinazolinoni sostituiti nella meta' 3-aromatica, procedimento per la loro produzione e loro impiego. | |
DE69007361D1 (de) | Festoxidbrennstoffzelle und Verfahren zu ihrer Herstellung. | |
DE58908935D1 (de) | Kaltvulkanisierbare Siliconkautschukmasse, Verfahren zu ihrer Herstellung und Verwendung. | |
ATE103989T1 (de) | Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung. | |
DE69012168D1 (de) | Nichtwässerige elektrochemische Zelle und Verfahren zu ihrer Herstellung. | |
ES509901A0 (es) | "digestor para la fermentacion celulosica, para la produccion de metano por fermentacion anaerobia". | |
DE3862788D1 (de) | Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung. | |
DE3584839D1 (de) | Zubereitung fuer die zellkultur, ihre herstellung und verwendung. | |
ES2047946T3 (es) | Metodos de cultivos celulares para producir proteina c activada. | |
ATE34386T1 (de) | 1,2,3,4-tetrahydro-1-aminomethyl-4-phenylisochinoline und verfahren zu ihrer herstellung. | |
JPS5411233A (en) | Anitidote | |
DE3675631D1 (de) | In-vitro-kulturverfahren. | |
DE3583601D1 (de) | Plasmid, verfahren zu dessen herstellung, dieses plasmid enthaltender mikroorganismus und verfahren zur zuechtung des mikroorganismus. | |
JPS5397241A (en) | Air conditioner | |
AR240829A2 (es) | Procedimiento para aislar levamisol de tetramisol | |
EP0342422A3 (en) | Process for the preparation of 2',3'-dideoxynucleosides, and intermediates used therein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20081221 |